Segmentation by type disaggregates the market into Antifungal, Antibacterial, Moisturizing, and Medicated sprays, each addressing a specific therapeutic pathway. Antifungal sprays, comprising roughly 28 % of the product mix, contain agents such as miconazole that target dermatophyte infections common in humid climates. Antibacterial variants, about 27 % of the market, employ broad‑spectrum compounds like chlorhexidine to curb secondary bacterial colonization on compromised skin. Moisturizing sprays, representing 22 % of sales, rely on humectants and ceramide precursors to restore epidermal hydration, appealing to owners seeking preventive care. Medicated sprays, the remaining 23 %, integrate corticosteroids or calcineurin inhibitors for severe inflammatory disorders, commanding premium pricing due to regulatory oversight. By quantifying each type’s share, analysts can map formulation trends, forecast R&D investment, and assess regulatory impact, thereby refining the overall market taxonomy for Pet Skin Treatment Spray.